Concord Drugs Limited

BSE:538965 Stock Report

Market Cap: ₹379.3m

Concord Drugs Past Earnings Performance

Past criteria checks 0/6

Concord Drugs's earnings have been declining at an average annual rate of -13.2%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 3% per year.

Key information

-13.2%

Earnings growth rate

-14.5%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate-3.0%
Return on equity-1.5%
Net Margin-1.0%
Next Earnings Update11 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Concord Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:538965 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24525-5560
30 Jun 244760620
31 Mar 244495610
31 Dec 2341610570
30 Sep 2342317550
30 Jun 2348513510
31 Mar 2352110490
31 Dec 2255391040
30 Sep 2255281030
30 Jun 22513111020
31 Mar 22590161000
31 Dec 2151919450
30 Sep 2146742420
30 Jun 2153538390
31 Mar 2151433380
31 Dec 2056130380
30 Sep 205884360
30 Jun 205634360
31 Mar 205143360
31 Dec 195274310
30 Sep 195104300
30 Jun 194844330
31 Mar 194824260
31 Dec 185501210
30 Sep 185174210
30 Jun 184405190
31 Mar 185193210
31 Dec 17522-13320
30 Sep 17554-4310
30 Jun 176561280
31 Mar 175762280
31 Dec 1649313260
30 Sep 1653519220
30 Jun 1651521190
31 Mar 1650917160
31 Dec 154742780
30 Sep 15443970
30 Jun 15421860
31 Mar 15404760
31 Dec 143884130
30 Sep 143754130
30 Jun 14359470
31 Mar 143413120

Quality Earnings: 538965 is currently unprofitable.

Growing Profit Margin: 538965 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 538965 is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.

Accelerating Growth: Unable to compare 538965's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 538965 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.5%).

Return on Equity

High ROE: 538965 has a negative Return on Equity (-1.5%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 14:04
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Concord Drugs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution